CHronic Nonbacterial Osteomyelitis International Registry

Summary

The objective of the study is to establish a prospective disease registry for chronic recurrent multifocal osteomyelitis (CRMO)/chronic nonbacterial osteomyelitis (CNO) in order to investigate the natural history of the disease and the responses of patients to different clinical managements over 10 years.

Conditions

• Chronic Nonbacterial Osteomyelitis
• Chronic Recurrent Multifocal Osteomyelitis

Interventions

DRUG

Methotrexate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Sulfasalazine

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Leflunomide

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Pamidronate

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Zoledronic acid

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Etanercept

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Adalimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Certolizumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Infliximab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

Golimumab

second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs

DRUG

NSAID

first-line treatment

Sponsors & Collaborators

• Boston Children's Hospital, Boston, MA, USA

  collaborator OTHER

• Hospital for Special Surgery, New York

  collaborator OTHER

• Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA

  collaborator UNKNOWN

• Riley Children's Hospital, Indianapolis, IN, USA

  collaborator UNKNOWN

• University of North Carolina, Chapel Hill, NC, USA

  collaborator UNKNOWN

• Royal Children's Hospital

  collaborator OTHER

• Hacettepe University, Ankara, Turkey

  collaborator UNKNOWN

• Bambino Gesù Children's Hospital, Rome, Italy

  collaborator UNKNOWN

• University of British Columbia, Vancouver, BC, Canada

  collaborator UNKNOWN

• Meyer Children's Hospital, Florence, Italy

  collaborator UNKNOWN

• Mansoura University

  collaborator OTHER

• University of Utah, Salt Lake City, UT, USA

  collaborator UNKNOWN

• University of Iowa Carver College of Medicine, Iowa City, IA, USA

  collaborator UNKNOWN

• Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA

  collaborator UNKNOWN

• Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia

  collaborator UNKNOWN

• Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK

  collaborator UNKNOWN

• University of Calgary, Calgary, Alberta, Canada

  collaborator UNKNOWN

• Seattle Children's Hospital

  lead OTHER

Eligibility

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-08-01

Primary Completion

2028-08-31

Completion

2050-08-31

Countries

• United States

Study Locations